On Monday, the U.S. Food and Drug Administration (FDA) approved Aduhelm (aducanumab) for the treatment of Alzheimer’s disease. Aduhelm was approved using the accelerated approval pathway, the FDA noted, which can be used for a drug for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.Continue Reading